Literature DB >> 2929585

Reversal of bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders.

L Talarico1, B C Wolf, A Kumar, L R Weintraub.   

Abstract

Bone marrow fibrosis is a characteristic finding in agnogenic myeloid metaplasia and in the spent phase of polycythemia vera. It is commonly believed that the reticulin deposition is irreversible. However, we report four patients who demonstrated clinical and laboratory evidence of transition from myelofibrosis to polycythemia. The transition was documented by improvement in the hemoglobin concentration and by determination of the Cr51 red blood cell mass, accompanied by a resolution of the fibrosis on serial bone marrow biopsies. Two of the patients had been treated with alkylating agents and splenectomy, one with myelosuppressive therapy without splenectomy, and one with splenectomy alone. These findings indicate that bone marrow fibrosis in the chronic myeloproliferative disorders is not always an irreversible phenomenon. Pathogenetic implications will be discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2929585     DOI: 10.1002/ajh.2830300411

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  1 in total

1.  The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Authors:  Annet Kirabo; Sung O Park; Anurima Majumder; Meghanath Gali; Mary K Reinhard; Heather L Wamsley; Zhizhuang Joe Zhao; Christopher R Cogle; Kirpal S Bisht; György M Keserü; Peter P Sayeski
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.